|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.30 EUR | -1.89% |
|
+0.25% | +15.27% |
| 07-11 | BIOMERIEUX : Attractiveness reinforced |  |
| 06-16 | BioMérieux S.A. acquired Key Assets of Day Zero Diagnostics Inc. | CI |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Medical Testing, Analyzing, and Diagnostic Equipment | ||||||||||
Clinical Applications | 2.66B | 2.88B | 3.04B | 3.1B | 3.37B | |||||
Gross Profit | 1.55B | 1.71B | 1.74B | 1.76B | 1.9B | |||||
Operating Income | 592M | 736M | 539M | 377M | 581M | |||||
Industrial Applications | 455M | 492M | 549M | 575M | 606M | |||||
Gross Profit | 201M | 246M | 270M | 297M | 307M | |||||
Operating Income | 31.7M | 59.6M | 44.2M | 60.5M | 51.8M | |||||
Vitro Diagnostics | - | - | - | - | - | |||||
Interest Expense | - | - | - | - | - | |||||
Income Tax Expense | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Gross Profit | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
Gross Profit | -800K | 3.8M | -700K | - | 3.3M | |||||
Operating Income | -10.9M | 6M | 3.7M | 1.6M | -18.4M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Americas | 1.59B | 1.67B | 1.84B | 1.85B | 2.05B | |||||
Total Assets | 1.01B | 1.12B | 1.91B | 2.08B | 2.4B | |||||
Gross Profit | 1.07B | 1.16B | 1.27B | 1.25B | 1.4B | |||||
Operating Income | 753M | 886M | 933M | 906M | 1.07B | |||||
Europe, The Middle East and Africa (EMEA) Excluding France | 803M | 902M | 901M | - | 1.03B | |||||
Total Assets | 397M | 513M | 838M | 901M | 930M | |||||
Asia-Pacific (ASPAC) | 505M | 580M | 624M | 638M | 656M | |||||
Total Assets | 217M | 264M | 363M | 247M | 274M | |||||
Gross Profit | 256M | 325M | 330M | 307M | 311M | |||||
Operating Income | 168M | 232M | 222M | 193M | 182M | |||||
France | 219M | 222M | 220M | - | 240M | |||||
Total Assets | 376M | 398M | 411M | 432M | 458M | |||||
Corporate | 3.5M | 3.3M | 2.6M | 900K | 600K | |||||
Total Assets | 1.27B | 1.24B | 761M | 714M | 686M | |||||
Gross Profit | -164M | -206M | -214M | -135M | -195M | |||||
Operating Income | -737M | -836M | -1.01B | -1.1B | -1.15B | |||||
Unallocated Applied Maths | - | - | - | - | - | |||||
Unallocated R&D-Related Revenue | - | - | - | - | - | |||||
Latin America | - | - | - | - | - | |||||
North America | - | - | - | - | - | |||||
Europe, The Middle East and Africa (EMEA) | - | - | - | 1.19B | - | |||||
Total Assets | - | - | - | - | - | |||||
Gross Profit | 596M | 688M | 627M | 634M | 702M | |||||
Operating Income | 429M | 519M | 441M | 438M | 520M |
- Stock Market
- Equities
- BIM Stock
- Financials bioMérieux
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition